73,405 Shares in Illumina, Inc. $ILMN Bought by Aware Super Pty Ltd as trustee of Aware Super

Aware Super Pty Ltd as trustee of Aware Super bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the 1st quarter, HoldingsChannel.com reports. The firm bought 73,405 shares of the life sciences company’s stock, valued at approximately $9,048,000.

Other hedge funds also recently modified their holdings of the company. Elyxium Wealth LLC purchased a new position in Illumina during the 4th quarter valued at about $25,000. Board of the Pension Protection Fund purchased a new stake in Illumina in the 4th quarter worth approximately $26,000. Creative Capital Management Investments LLC grew its stake in Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. acquired a new position in Illumina in the 4th quarter worth about $26,000. Finally, Laurel Wealth Advisors LLC purchased a new stake in shares of Illumina during the 4th quarter worth about $26,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

ILMN has been the subject of several research reports. TD Cowen reiterated a “hold” rating on shares of Illumina in a report on Wednesday. Leerink Partners lifted their target price on Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a research note on Thursday, May 14th. Barclays increased their price target on shares of Illumina from $122.00 to $145.00 and gave the company an “underweight” rating in a research note on Wednesday, June 24th. Finally, Guggenheim increased their target price on Illumina from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Nine analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $156.88.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $186.65 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The stock has a market capitalization of $28.24 billion, a PE ratio of 33.94, a P/E/G ratio of 3.56 and a beta of 1.47. The business has a fifty day moving average price of $166.44 and a two-hundred day moving average price of $143.34. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $196.66.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts predict that Illumina, Inc. will post 5.21 earnings per share for the current fiscal year.

Insider Activity

In other Illumina news, SVP Patricia Leckman sold 783 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the transaction, the senior vice president directly owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the transaction, the director directly owned 2,830,452 shares in the company, valued at $463,146,860.76. This trade represents a 7.67% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 1,003,769 shares of company stock worth $155,710,908. 2.90% of the stock is owned by corporate insiders.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.